PeptideAmerica

Reference

Reference tables

Each table below is read out of the same dated ledger the molecule index renders. No cell on any of them is typed by hand, which is what lets a table stay correct when a status flips: one edit to the registry re-renders every row on every page at once.

Each table states its denominator above the data. A count on these pages is a count of the substances this index tracks, stated as such; where a total exists only in a source this index has not verified, the table declines to print one rather than estimating it.

  1. How did the advisory committee vote on each peptide, and what does a vote do?

    The July 2026 vote ledger

    The committee recommended six peptides for the section 503A list and rejected one; the votes are advisory, FDA rulemaking must finish before any of the six may be compounded, and as of the dates below none may.

    7 rows · 5 columns · 7 molecules

  2. What happened to United States peptide compounding law in 2026, in order?

    The 2026 record

    Twelve peptides left a prohibition category in April and an advisory committee recommended six of them for listing in July; no peptide reviewed in 2026 became lawful to compound, because the FDA has issued no final rule.

    25 rows · 3 columns · 16 molecules

  3. What became of each peptide's nomination to the 503A bulks list?

    The nomination tracker

    Four dispositions account for every molecule in this index, and two of them — removal without listing, and withdrawal by the nominators — are routinely reported as approvals when they are the opposite of one.

    16 rows · 4 columns · 16 molecules

  4. The peptides removed from Category 2 in April 2026 — are they lawful now?

    Removal is not permission

    No. Removal ended an explicit prohibition and conferred no authorization; the substances were not added to Category 1, they sit on no list, and no lawful compounding route followed from the removal.

    8 rows · 3 columns · 8 molecules

  5. Which peptides in this index are actually approved drugs?

    Approved peptide drugs

    Three, and their approvals are narrow: an approval belongs to a product in a stated indication, not to a molecule in every use a seller can imagine for it.

    3 rows · 4 columns · 3 molecules

What the tables do not do

They do not adjudicate a named seller, and they do not anticipate rulemaking: a recommended molecule is recorded as recommended and pending, whatever the market expects. The method states both rules, the evidence reviews argue from the same record, and the glossary defines the terms every table uses.